# US 12,178,867 B2 · MHC class i associated peptides for prevention and treatment of multiple flavi virus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,178,867 B2 - Document ID: US12178867B2 - Status: Granted - Kind: B2 - Application number: 18/332,022 - Filed: 2023-06-09 - Published: 2023-11-02 - Granted: 2024-12-31 - Earliest claimed: 2018-01-06 - Assignees: Emergex Vaccines Holding Ltd. - Applicants: Emergex Vaccines Holding Limited - Inventors: Ramila Philip - Web page: https://patentgrep.com/patent/US12178867B2 ## CPC - A61K 39/12: Viral antigens - A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle} - C07K 14/1816: {Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus} - A61K 2039/60: {characteristics by the carrier linked to the antigen} - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes. ## Claims ### Claim 1 A vaccine composition comprising a conjugate, the conjugate comprising a flavivirus peptide attached to a gold nanoparticle, wherein: (i) the flavivirus peptide is 8 to 30 amino acids in length, and comprises a CD8+ T cell epitope comprising the amino acid sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 18, or a variant thereof which differs from SEQ ID NO: 15 or SEQ ID NO: 18 by one amino acid substitution, deletion or insertion; and (ii) the gold nanoparticle is coated with galactose and/or GlcNAc. ### Claim 2 (depends on 1) The vaccine composition of claim 1, wherein the gold nanoparticle is coated with alpha-galactose and/or beta-GlcNAc. ### Claim 3 (depends on 1) The vaccine composition of claim 1, wherein the gold nanoparticle is coated with galactose and GlcNAc. ### Claim 4 (depends on 1) The vaccine composition of claim 1, wherein the flavivirus peptide is attached to the nanoparticle by a linker. ### Claim 5 (depends on 4) The vaccine composition of claim 4, wherein the linker has the structure: —S—(CH2)2—CONH-AAY- wherein the S is attached to the nanoparticle and AAY is a peptide joined to the N-terminus of the flavivirus peptide. ### Claim 6 (depends on 1) The vaccine composition of claim 1, wherein the variant differs from SEQ ID NO: 15 or SEQ ID NO: 18 by one conservative amino acid substitution. ### Claim 7 (depends on 1) The vaccine composition of claim 1, wherein the flavivirus peptide comprises the T cell epitope set forth in SEQ ID NO: 15. ### Claim 8 (depends on 1) The vaccine composition of claim 1, wherein the flavivirus peptide comprises the T cell epitope set forth in SEQ ID NO: 18. ### Claim 9 (depends on 1) The vaccine composition of claim 1, comprising a first conjugate and a second conjugate, each comprising a flavivirus peptide attached to a gold nanoparticle, wherein each flavivirus peptide is 8 to 30 amino acids in length, the gold nanoparticle is coated with galactose and GlcNAc and: (i) the first conjugate comprises a flavivirus peptide comprising a first CD8+ T cell epitope comprising the amino acid sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 18, or a variant thereof which differs from SEQ ID NO: 15 or SEQ ID NO: 18 by one amino acid substitution, deletion or insertion; and (ii) the second conjugate comprises a flavivirus peptide comprising a second CD8+ T cell epitope comprising the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 23, or a variant thereof which differs from any one of SEQ ID NOs: 1 to 23 by one amino acid substitution, deletion or insertion; wherein the first and second CD8+ T cell epitopes are different. ### Claim 10 (depends on 9) The vaccine composition of claim 9, comprising: (i) a conjugate comprising SEQ ID NO: 15 or a variant thereof; (ii) a conjugate comprising SEQ ID NO: 16 or a variant thereof; (iii) a conjugate comprising SEQ ID NO: 17 or a variant thereof; (iv) a conjugate comprising SEQ ID NO: 18 or a variant thereof; (v) a conjugate comprising SEQ ID NO: 19 or a variant thereof; (vi) a conjugate comprising SEQ ID NO: 20 or a variant thereof; (vii) a conjugate comprising SEQ ID NO: 21 or a variant thereof; (viii) a conjugate comprising SEQ ID NO: 22 or a variant thereof; and (ix) a conjugate comprising SEQ ID NO: 23 or a variant thereof; wherein said variants differ from each of SEQ ID NOs: 15 to 23 by one amino acid substitution, deletion or insertion. ### Claim 11 (depends on 10) The vaccine composition of claim 10, comprising: (i) a conjugate comprising SEQ ID NO: 15; (ii) a conjugate comprising SEQ ID NO: 16; (iii) a conjugate comprising SEQ ID NO: 17; (iv) a conjugate comprising SEQ ID NO: 18; (v) a conjugate comprising SEQ ID NO: 19; (vi) a conjugate comprising SEQ ID NO: 20; (vii) a conjugate comprising SEQ ID NO: 21; (viii) a conjugate comprising SEQ ID NO: 22; and (ix) a conjugate comprising SEQ ID NO: 23. ### Claim 12 (depends on 1) The vaccine composition of claim 1, further comprising a pharmaceutically acceptable diluent, carrier or excipient. ### Claim 13 (depends on 1) A method of treating or preventing a flavivirus infection in a subject, comprising administering the vaccine composition of claim 1 to an individual infected with, or at risk of being infected with, a flavivirus. ### Claim 14 (depends on 13) The method of claim 13, wherein the method is for preventing a flavivirus infection in a subject, and the individual is at risk of being infected with a flavivirus. ### Claim 15 (depends on 13) The method of claim 13, wherein the flavivirus infection is a Zika virus infection, West Nile virus infection, dengue virus infection, yellow fever virus infection, and/or Japanese encephalitis virus infection. ### Claim 16 (depends on 15) The method of claim 15, wherein the flavivirus infection is a dengue virus infection. ### Claim 17 (depends on 13) The method of claim 13, wherein the method comprises intradermal or transdermal administration of the vaccine composition to the individual. ### Claim 18 (depends on 2) The vaccine composition of claim 2, wherein the gold nanoparticle is coated with alpha-galactose and beta-GlcNAc. ### Claim 19 (depends on 1) A method of stimulating an immune response in an individual, comprising administering to the individual the vaccine composition of claim 1. ### Claim 20 (depends on 19) The method of claim 19, wherein the method comprises intradermal or transdermal administration of the vaccine composition to the individual.